Rigel Pharmaceuticals Files 8-K on Financials
Ticker: RIGL · Form: 8-K · Filed: May 7, 2024 · CIK: 1034842
| Field | Detail |
|---|---|
| Company | Rigel Pharmaceuticals Inc (RIGL) |
| Form Type | 8-K |
| Filed Date | May 7, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations
TL;DR
Rigel Pharma dropped an 8-K detailing their financial results - check it for the latest numbers.
AI Summary
Rigel Pharmaceuticals, Inc. filed an 8-K on May 7, 2024, to report on its results of operations and financial condition. The filing includes financial statements and exhibits related to the company's performance.
Why It Matters
This filing provides investors with crucial updates on Rigel Pharmaceuticals' financial health and operational performance, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial disclosure filing and does not inherently present new risks.
Key Players & Entities
- RIGEL PHARMACEUTICALS, INC. (company) — Registrant
- May 7, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 611 Gateway Boulevard, Suite 900 (address) — Principal executive offices
- South San Francisco, CA 94080 (address) — Principal executive offices
- (650) 624-1100 (phone_number) — Registrant's telephone number
FAQ
What specific financial information is being reported in this 8-K?
This 8-K reports on Rigel Pharmaceuticals, Inc.'s results of operations and financial condition, including financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 7, 2024.
Where is Rigel Pharmaceuticals, Inc. incorporated?
Rigel Pharmaceuticals, Inc. is incorporated in Delaware.
What is the principal executive office address for Rigel Pharmaceuticals, Inc.?
The principal executive office address is 611 Gateway Boulevard, Suite 900, South San Francisco, CA 94080.
What is the telephone number for Rigel Pharmaceuticals, Inc.?
The telephone number for Rigel Pharmaceuticals, Inc. is (650) 624-1100.
Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-05-07 16:16:15
Key Financial Figures
- $0.001 — h Registered Common Stock, par value $0.001 per share RIGL The Nasdaq Stock Mar
Filing Documents
- tm2413689d1_8k.htm (8-K) — 26KB
- tm2413689d1_ex99-1.htm (EX-99.1) — 105KB
- tm2413689d1_ex99-1img01.jpg (GRAPHIC) — 11KB
- 0001104659-24-058017.txt ( ) — 330KB
- rigl-20240507.xsd (EX-101.SCH) — 3KB
- rigl-20240507_lab.xml (EX-101.LAB) — 33KB
- rigl-20240507_pre.xml (EX-101.PRE) — 22KB
- tm2413689d1_8k_htm.xml (XML) — 4KB
02
Item 2.02. Results of Operations and Financial Condition. On May 7, 2024, Rigel Pharmaceuticals, Inc. (" Rigel ") announced certain financial results for its first quarter ended March 31, 2024. A copy of Rigel's press release, titled "Rigel Reports First Quarter 2024 Financial Results and Provides Business Update," is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. The information in this report, including the exhibit hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Rigel, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 99.1 Press Release, dated May 7, 2024, titled "Rigel Reports First Quarter 2024 Financial Results and Provides Business Update." 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 7, 2024 RIGEL PHARMACEUTICALS, INC. By: /s/ Ray Furey, J.D. Ray Furey, J.D. Executive Vice President, General Counsel and Corporate Secretary